(NewsNation) — The Food and Drug Administration will hold a meeting in July about whether to ease restrictions on access to peptides, the trending, underregulated injectable substances gripping the wellness community.
Peptides have surged in popularity, rapidly entering the commercial mainstream as claims circulate about anti-aging, muscle growth and enhanced cognitive function. A “gray market” has emerged online to meet demand, according to PBS, with companies creating compounded or unapproved formulations and adding “for research use only” disclaimers.
Inside the booming, gray-market world of injectable peptides
Where do peptides currently stand?
Overall, peptides have not yet been designated as outwardly unsafe or authorized. The upcoming FDA advisory meeting is set to assess whether to allow compounding pharmacies to produce seven different peptides.
The push for change has largely been led by Health Secretary Robert F. Kennedy Jr., who spoke out against the Biden administration banning compounding pharmacies from producing 19 research peptides due to safety concerns, according to NBC News.
In April, Kennedy reclassified 12 peptides as Category 1 substances, the first step toward allowing compounding pharmacies to produce them.
Many people have raised red flags, as most peptides have not been studied in humans, leaving little evidence of effectiveness. Additionally, the current landscape of online vending and self-administration has put many people off the substances.
However, many argue that offering peptides through licensed compounding pharmacies would shrink the underground market and lead to safer usage.
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The upcoming FDA decision
The FDA’s Pharmacy Compounding Advisory Committee will meet on July 23 and 24 to review the evidence on peptides. The committee is merely an advisor, meaning the FDA will have the final say on whether to allow these substances.
Dr. Anita Gupta, an anesthesiologist who served on the committee from 2020 to 2025, said the panel previously voted against making certain peptides available through compounding pharmacies, according to NBC News.
“Studies have begun to show that there are significant issues with some of these products. Some of them have heavy metals. Some have microbial contamination. Some are mislabeled,” Gupta told NBC.
The committee recently appointed nine new members to assist with the decision, which is due later this month.
Copyright 2026 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
For the latest news, weather, sports, and streaming video, head to NewsNation.